Related Experiment Video

Updated: May 23, 2026

Establishment of Coloproctitis Cancer Model in Mice and Evaluation of Therapeutic Effect of Chinese Medicine
06:24

Establishment of Coloproctitis Cancer Model in Mice and Evaluation of Therapeutic Effect of Chinese Medicine

Published on: October 13, 2023

Linaclotide in the management of gastrointestinal tract disorders

B E Lacy1, J M Levenick, M D Crowell

  • 1Dartmouth-Hitchcock Medical Center-Gastroenterology, Lebanon, New Hampshire 03756, USA. brian.lacy@hitchcock.org

Drugs of Today (Barcelona, Spain : 1998)
|March 31, 2012
PubMed

Insights

Chronic constipation and IBS-C affect many Americans, with limited treatment options. Linaclotide offers a new therapeutic approach for these prevalent gastrointestinal disorders.

Area of Science:

  • Gastroenterology
  • Pharmacology

Background:

  • Chronic constipation affects 15% of the U.S. population, impacting quality of life and healthcare costs.
  • Irritable bowel syndrome with constipation (IBS-C) affects up to 12% of the U.S. population, posing significant patient and healthcare burdens.
  • Current treatments for chronic constipation and IBS-C are not universally effective, necessitating novel therapeutic options.

Purpose of the Study:

  • To review the pharmacology, pharmacokinetics, preclinical data, clinical studies, and safety data of linaclotide.
  • To evaluate linaclotide as a potential treatment for chronic constipation and IBS-C.

Main Methods:

  • Review of preclinical data.
  • Analysis of clinical trial results.
  • Evaluation of safety and pharmacokinetic data.

Main Results:

  • Linaclotide's pharmacological profile and pharmacokinetic properties.
  • Clinical efficacy and safety data from studies in patients with chronic constipation and IBS-C.
  • Comparison with existing therapeutic options.

Conclusions:

  • Linaclotide demonstrates potential as a new treatment for chronic constipation and IBS-C.
  • Further research and clinical application are warranted based on presented data.
  • Linaclotide may address unmet needs in managing these prevalent gastrointestinal conditions.

More Related Videos

Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease03:50

Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease

Published on: August 18, 2023

Related Concept Videos

Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs Affecting GI Tract Motility: Other Laxatives01:20

Drugs Affecting GI Tract Motility: Other Laxatives

Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives01:22

Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives

Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This makes...